Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice

Virology Journal

Volumn 9, Issue , 2012, Pages

  Huang, Baoying ^a   Wang, Wenling ^a   Li, Renqing ^a   Wang, Xiuping ^a   Jiang, Tao ^a   Qi, Xiangrong ^a   Gao, Yingying ^a   Tan, Wenjie ^a   Ruan, Li ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RECOMBINANT NUCLEOPROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS NUCLEOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; BACTERIAL STRAIN; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI; EX VIVO STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MOUSE; NONHUMAN; PROTEIN PURIFICATION; SURVIVAL RATE; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PLASMIDS; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS; TRANSFORMATION, GENETIC; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL CORE PROTEINS;

ESCHERICHIA COLI; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; VACCINIA VIRUS;

EID: 84871574987     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-322     Document Type: Article

References (55)

1. Influenza. Cox NJ, Subbarao K, Lancet 1999 354 1277 82 10.1016/S0140-6736(99)01241-6 10520648 (Pubitemid 29469365)
2. Vaccines for seasonal and pandemic influenza. Nichol KL, Treanor JJ, J Infect Dis 2006 194 Suppl 2 111 S118 17163383
3. Influenza vaccines for the future. Lambert LC, Fauci AS, N Engl J Med 2010 363 21 2036 44 10.1056/NEJMra1002842 21083388
4. Moving influenza vaccines forward. Sambhara S, Stephenson I, Expert Rev Vaccines 2009 8 4 375 7 10.1586/erv.09.10 19348553
5. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. Centers for Disease Control and Prevention (CDC), Morb Mortal Wkly Rep 2011 60 33 1128 32
6. Influenza vaccine: the challenge of antigenic drift. Carrat F, Flahault A, Vaccine 2007 25 39-40 6852 62 17719149 (Pubitemid 47398929)
7. The genesis of a pandemic Influenza virus. Russell CJ, Webster RG, Cell 2005 123 3 368 71 10.1016/j.cell.2005.10.019 16269328 (Pubitemid 41546667)
8. Making better influenza virus vaccines? Palese P, Emerg Infect Dis 2006 12 1 61 65 10.3201/eid1201.051043 16494719 (Pubitemid 43143537)
9. Preparing for pandemic vaccination: an international policy agenda for vaccine development. Fedson DS, J Public Health Policy 2005 26 1 4 29 10.1057/palgrave.jphp.3200008 15906873 (Pubitemid 40632275)
10. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. Shu LL, Bean WJ, Webster RG, J Virol 1993 67 5 2723 9 8474171 (Pubitemid 23118870)
11. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. Portela A, Digard P, J Gen Virol 2002 83 Pt 4 723 34 11907320 (Pubitemid 34284855)
12. Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusic V, Tan TW, August JT, PLoS One 2007 2 11 1190 10.1371/journal.pone. 0001190 18030326 (Pubitemid 351638062)
13. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL, Vaccine 2009 27 47 6512 21 10.1016/j.vaccine.2009.08.053 19729082
14. Cytotoxic T-cell immunity to influenza. McMichael AJ, Gotch FM, Noble GR, Beare PA, N Engl J Med 1983 309 1 13 17 10.1056/NEJM198307073090103 6602294 (Pubitemid 13062888)
15. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, DeWitt C, Liu X, Wang S, Liu MA, Donnelly JJ, Caulfield MJ, J Virol 1998 72 7 5648 53 9621023 (Pubitemid 28283349)
16. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus [J]. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD, J Immunol 2008 181 6 4168 76 18768874
17. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms [J]. Rangel-Moreno J, Carragher DM, Misra RS, Kusser K, Hartson L, Moquin A, Lund FE, Randall TD, J Immunol 2008 180 1 454 63 18097047
18. Heterologous protection against influenza by injection of DNA encoding a viral protein. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Science 1993 259 5102 1745 9 10.1126/science.8456302 8456302 (Pubitemid 23114660)
19. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Nabel GJ, Vaccine 2005 23 46-47 5401 10
20. Li RQ, Immunologic characteristics of non-major protective antigens for influenza A viru Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 2006
21. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, Shmarov MM, Zhirnov OP, Varich NP, Ilyinskii PO, Shneider AM, Arch Virol 2006 151 5 921 31 10.1007/s00705-005-0676-9 16292596
22. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Roy S, Kobinger GP, Lin J, Figueredo J, Calcedo R, Kobasa D, Wilson JM, Vaccine 2007 25 39-40 6845 51 17728024 (Pubitemid 47398928)
23. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Jeon SH, Yedidia TB, Arnon R, Vaccine 2002 20 21-22 2772 80 12034104 (Pubitemid 34597137)
24. Purified influenza virus nucleoprotein protects mice from lethal infection [J]. Wraith DC, Vessey AE, Askonas BA, J Gen Virol 1987 68 2 433 40 10.1099/0022-1317-68-2-433 3493324 (Pubitemid 17007830)
25. Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005. Hampson AW, Osterhaus AD, Pervikov Y, Kieny MP, Vaccine 2006 24 23 4897 900 10.1016/j.vaccine.2006.03.035 16823947 (Pubitemid 43782678)
26. Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Zhirnov OP, Isaeva EI, Konakova TE, Thoidis G, Piskareva LM, Akopova II, Kartashov A, Altstein AD, Ilyinskii PO, Shneider AM, Influenza Other Respi Viruses 2007 1 71 79 10.1111/j.1750-2659.2007.00010.x 18784792
27. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ, Rolland A, Kaslow DC, Smith LR, Hum Vaccine 2007 3 5 157 64 10.4161/hv.3.5.4175 (Pubitemid 47598172)
28. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: Cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Lo CY, Wu Z, Misplon JA, Price GE, Pappas C, Kong WP, Tumpey TM, Epstein SL, Vaccine 2008 26 17 2062 72 18378366
29. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC, Clin Infect Dis 2011 52 1 1 7 10.1093/cid/ciq015 21148512
30. A preliminary assessment of the efficacy of a T cell-based influenza vaccine, MVA-NP+M1, in humans. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC, Clin Infect Dis 2012 55 1 19 25 10.1093/cid/cis327 22441650
31. Vaccine development strategies for improving immunization: the role of modern immunology. Levine MM, Sztein MB, Nature immunity 2004 5 5 460 6 10.1038/ni0504-460 (Pubitemid 38660452)
32. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs [J]. Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, Jacobs A, Liu G, Huang Y, Desai P, Maksymiuk G, Takahashi V, Umlauf S, Reiserova L, Bell R, Li H, Zhang Y, McDonald WF, Powell TJ, Tussey L, PLoS One 2008 3 5 2257 10.1371/journal.pone. 0002257 18493310
33. Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Biesova Z, Miller MA, Schneerson R, Shiloach J, Green KY, Vaccine 2009 27 6234 8 10.1016/j.vaccine.2009.07.107 19686692
34. An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. Aguilar-Yáñez JM, Portillo-Lara R, Mendoza-Ochoa GI, García-Echauri SA, López-Pacheco F, Bulnes-Abundis D, Salgado-Gallegos J, Lara-Mayorga IM, Webb-Vargas Y, León-Angel FO, Rivero-Aranda RE, Oropeza-Almazán Y, Ruiz-Palacios GM, Zertuche-Guerra MI, DuBois RM, White SW, Schultz-Cherry S, Russell CJ, Alvarez MM, PLoS One 2010 5 7 11694 10.1371/journal.pone.0011694 20661476
35. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Guo L, Zheng M, Ding Y, Li D, Yang Z, Wang H, Chen Q, Sui Z, Fang F, Chen Z, Arch Virol 2010 155 11 1765 75 10.1007/s00705-010-0756-3 20652335
36. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines. Thueng-in K, Maneewatch S, Srimanote P, Songserm T, Tapchaisri P, Sookrung N, Tongtawe P, Channarong S, Chaicumpa W, Vaccine 2010 28 41 6765 77 10.1016/j.vaccine.2010.07.065 20688037
37. Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. Sonoguchi T, Naito H, Hara M, Takeuchi Y, Fukumi H, J Infect Dis 1985 151 1 81 8 10.1093/infdis/151.1.81 3965596 (Pubitemid 15192884)
38. Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. Tamura M, Webster RG, Ennis FA, J Virol 1994 68 6 3499 504 8189489 (Pubitemid 24177373)
39. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Moss B, Proc Natl Acad Sci U S A 1996 93 21 11341 8 10.1073/pnas.93.21.11341 8876137 (Pubitemid 26347123)
40. Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Smith GL, Levin JZ, Palese P, Moss B, Virology 1987 160 2 336 45 10.1016/0042-6822(87)90004-3 3310381
41. The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Andrew ME, Coupar BE, Boyle DB, Ada GL, Scand J Immunol 1987 25 1 21 8 10.1111/j.1365-3083.1987. tb01042.x 3492756 (Pubitemid 17144580)
42. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Rimmelzwaan GF, Sutter G, Expert Rev Vaccines 2009 8 4 447 54 10.1586/erv.09.4 19348560
43. The immunological effect of a Hepatitis a-vaccinia recombinant virus (VMS11HAV25) in human. Guo KJ, Ruan L, Wang XJ, Yi Y, Liu CB, Ren YH, Zhang YC, Liu XH, Gao SJ, Yang JW, Ju JM, Chin J Microbiol Immunol 1992 2 8 137 40
44. A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. Gu S, Huang T, Miao Y, Ruan L, Zhao Y, Han C, Xiao Y, Zhu J, Wolf H, Chin Med Sci J 1991 6 241 43 1667485
45. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, Haynes L, Randall TD, Lund FE, Kaminski DA, J Virol 2011 85 10 5027 35 10.1128/JVI.00150-11 21367900
46. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. Lamere MW, Lam HT, Moquin A, Haynes L, Lund FE, Randall TD, Kaminski DA, J Immunol 2011 186 7 4331 9 10.4049/jimmunol.1003057 21357542
47. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity. Ohba K, Yoshida S, Zahidunnabi Dewan M, Shimura H, Sakamaki N, Takeshita F, Yamamoto N, Okuda K, Vaccine 2007 25 21 4291 300 10.1016/j.vaccine.2007.02.074 17403560 (Pubitemid 46635935)
48. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. Fu TM, Guan L, Friedman A, Schofield TL, Ulmer JB, Liu MA, Donnelly JJ, J Immunol 1999 162 7 4163 70 10201942 (Pubitemid 29314802)
49. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, Osterhaus AD, Rimmelzwaan GF, Vaccine 2007 25 4 612 20 10.1016/j.vaccine.2006.08.036 17005299 (Pubitemid 44856111)
50. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Gioia C, Castilletti C, Tempestilli M, Piacentini P, Bordi L, Chiappini R, Agrati C, Squarcione S, Ippolito G, Puro V, Capobianchi MR, Poccia F, Emerg Infect Dis 2008 14 1 121 8 10.3201/eid1401.061283 18258091
51. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF, J Virol 2008 82 11 5161 6 10.1128/JVI.02694-07 18353950 (Pubitemid 351705225)
52. Efficient soluble expression and purification of influenza A nucleoprotein in Escherichia coli. Huang BY, Wang WL, Wang XP, Jiang T, Tan WJ, Ruan L, Bing Du Xue Bao 2011 27 1 50 7 21462506
53. Epitope screening of influenza A virus nucleocapsid protein in BALB/c mice by enzyme-linked immuno-blot and its correlation with CTL epitope. Wang WL, Huang BY, Wang XP, Tan WJ, Ruan L, Letters in Biotechnology 2008 19 3 1 5
54. Guo YJ, Chen XW, Influenza virus and its experimental techniques China Three Gorges Press, Beijing 1997 1 70
55. Cutting edge: rapid in vivo CTL activity by polyoma virus-specific effector and memory CD8+ T cells. Byers AM, Kemball CC, Moser JM, Lukacher AE, J Immunol 2003 171 1 17 21 12816977 (Pubitemid 36745267)